Company intelligence / Profile preview

Ambryx Biotechnology

La Jolla, California, United States

Ownership: Private
Development stage: Preclinical

Overview

Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications. Their lead candidates include ARX517 targeting PSMA for prostate cancer and ARX788 targeting HER2 for breast cancer. The company's proprietary ADC technology offers unique advantages in the conjugation of stable antibodies and cytotoxic linker payloads.

Therapeutic areas: Oncology
Modalities: Antibody Drug Conjugates (ADCs)Immuno-oncology conjugatesBispecificsEngineered biologics
Industry: Biotech

Partnerships

Johnson & JohnsonMultiple pharmaceutical companies (unspecified)

Beyond the preview

Go deeper on Ambryx Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ambryx Biotechnology.

Explore the full profile